EUVIMEDEUVIMED entdecken
Multizentrische StudieLeitlinieOpen Access · CC BY 4.0

Prescription of Guideline-Directed Medical Therapy in Heart Failure: Impact on Mortality and Readmission

Martin Möckel iD, Samipa Pudasaini, Kristina Feldmann, Henning Thomas Baberg, Benny Levenson, Jürgen Malzahn, Thomas Mansky, Guido Michels, Christian Günster iD, Elke Jeschke iD

ESC Heart Failure · 2025

DOI: 10.1002/ehf2.15280 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Martin Möckel und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency and Acute Medicine, Campus Virchow-Klinikum and Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Corporate Member …. Hauptthemen laut MEDLINE: Heart Failure, Patient Readmission, Practice Guidelines as Topic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The 2021 European heart failure (HF) guidelines recommend the combination of four drugs as a standard therapy (angiotensin-converting enzyme inhibitor [ACEI]/angiotensin receptor blocker [ARB]/angiotensin receptor-neprilysin inhibitor [ARNI]; beta-blocker (BB); mineralocorticoid receptor antagonist [MRA]; sodium-glucose co-transporter 2 inhibitor [SGLT2i]) in patients with heart failure and reduced ejection fraction (HFrEF). We investigated if the use of this combined treatment (as opposed to the outdated two-drug ACEI/ARB and BB therapy) yields a favourable outcome regarding mortality and readmission and evaluated whether an increase in adoption of the newly endorsed therapy can already be observed in clinical routine. Methods and results We included anonymous data from all patients who were insured at Germany’s largest health insurer (Allgemeine Ortskrankenkasse [AOK]) and had a claims record for hospitalization (2019–2021) with the main diagnosis of HF. Mortality and readmission within 91–365 days following the index stay were analysed, and the impact of medication on outcome was compared. 315 342 cases of hospitalization due to HF were included (median 80 years [IQR 72–86], 53.7% female). HF drug prescription rates were as follows: ACEI 46.3%, ARB 31.8%, ARNI 12.1%, BB 80.9%, MRA 35.6%, SGLT2i 7.3%. Treatment combinations were prescribed in 35.9% (two-drug) and 3.7% (four-drug). Total mortality was 18.0%, all-cause readmission 32.0%, and HF readmission 16.0%. Mortality risk was significantly lower (adjusted HR = 0.92 [95% CI 0.86–0.97]) with the four- versus two-drug treatment. Kaplan–Meier survival was 88.2% for the four-drug therapy [95% CI: 87.6%–88.8%] and 83.1% for the two-drug therapy [95% CI: 82.9%–83.3%]). Similar benefits were visible for the readmission rates due to all causes (HR = 0.76 [0.73–0.80]) and readmission due to HF (HR = 0.90 [0.85–0.95]).

Conclusions

Our study suggests that the newly recommended four-drug therapy may lead to lower mortality and readmission rates compared to the outdated two-drug therapy. However, the overall adoption of the four-drug therapy remains limited.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailurePatient ReadmissionPractice Guidelines as TopicHumansFemaleMaleAgedRetrospective StudiesAngiotensin-Converting Enzyme InhibitorsAdrenergic beta-AntagonistsAngiotensin Receptor AntagonistsMineralocorticoid Receptor AntagonistsSurvival RateDrug Therapy, CombinationAged, 80 and overGermanyStroke VolumeFollow-Up StudiesMiddle Aged

Stichwörter der Autor:innen

Drug therapyGuideline adherenceHeart failureMortalityReadmission

Substanzen

Angiotensin-Converting Enzyme InhibitorsAdrenergic beta-AntagonistsAngiotensin Receptor AntagonistsMineralocorticoid Receptor Antagonists

Autor:innen und Institutionen

  • Department of Emergency and Acute Medicine, Campus Virchow-Klinikum and Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität and Humboldt-Universität zu Berlin, Berlin, Germa…
  • Department of Cardiology and Nephrology, Helios Klinikum, Berlin-Buch and Medical School Berlin, Berlin, Germany.
  • German Society of Cardiologists in Private Practise (BNK), Berlin, Germany.
  • Federal Association of the Local Health Care Funds (AOK), Berlin, Germany.
  • Faculty of Economics and Management, Division of Structural Development and Quality Management in Healthcare, Technische Universität Berlin, Berlin, Germany.
  • Department of Emergency Medicine, Hospital of the Barmherzige Brüder, Trier, Germany.

ORCID-Profile: Martin Möckel, Christian Günster, Elke Jeschke

Zitieren

APA

Möckel, M., Pudasaini, S., Feldmann, K., Baberg, H. T., Levenson, B., Malzahn, J., Mansky, T., Michels, G., Günster, C., & Jeschke, E. (2025). Prescription of Guideline-Directed Medical Therapy in Heart Failure: Impact on Mortality and Readmission. ESC Heart Failure. https://doi.org/10.1002/ehf2.15280

Vancouver

Möckel M, Pudasaini S, Feldmann K, Baberg HT, Levenson B, Malzahn J, et al. Prescription of Guideline-Directed Medical Therapy in Heart Failure: Impact on Mortality and Readmission. ESC Heart Failure. 2025. doi:10.1002/ehf2.15280

BibTeX
@article{Mckel2025,
  author = {Möckel, Martin and Pudasaini, Samipa and Feldmann, Kristina and Baberg, Henning Thomas and Levenson, Benny and Malzahn, Jürgen and Mansky, Thomas and Michels, Guido and Günster, Christian and Jeschke, Elke},
  title = {Prescription of Guideline-Directed Medical Therapy in Heart Failure: Impact on Mortality and Readmission},
  journal = {ESC Heart Failure},
  year = {2025},
  doi = {10.1002/ehf2.15280}
}
Kostenlos starten →